Technical Articles

CAR-T therapy has demonstrated promising efficacy in patients with hematologic malignancies, but it is often accompanied by clinical toxicities such as cytokine release syndrome, which not only affects patient health but also increases the medical burden.

FITC-Labeled SLAMF7/CRACC/CD319 Fc Chimera Protein is a high-performance fluorescently labeled fusion protein with critical value in immunotherapy research for hematologic malignancies such as multiple myeloma.